CTOs on the Move

Allegro Ophthalmics

www.allegroeye.com

 
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.allegroeye.com
  • 31473 Rancho Viejo Road Suite 204
    San Juan Capistrano, CA USA 92675
  • Phone: 949.940.8130

Executives

Name Title Contact Details

Similar Companies

DrugSense

DrugSense is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bactolac Pharmaceutical Inc

We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide

Aktiv Pharma Group

Aktiv Pharma Group is a company that develops drug delivery technology for emergency situations, with a focus on the ARAI auto injector for opioid overdose, hypoglycemia, and severe allergies like anaphylaxis.

Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.